Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic
NCT ID: NCT07329907
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
126 participants
INTERVENTIONAL
2023-12-01
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts
NCT05652998
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
NCT05291845
Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT06749665
Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts
NCT05429151
Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart
NCT06233019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
topical monotherapy
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Salicylic Acid/Lactic Acid Topical Solution
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Intralesional Monotherapy
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Candida Antigen Intralesional Injection
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Combination Therapy
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Candida Antigen and Salicylic Acid/Lactic Acid
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Salicylic Acid/Lactic Acid Topical Solution
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Candida Antigen Intralesional Injection
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Candida Antigen and Salicylic Acid/Lactic Acid
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged 5 to 60 years.
3. Eligible for both topical and intralesional treatments.
4. No prior wart treatment for at least 1 month.
Exclusion Criteria
2. Immunosuppression or use of immunosuppressive drugs.
3. Known sensitivity to study ingredients.
4. Systemic/local inflammation or infection.
5. History of bleeding/clotting disorder, or use of anticoagulants/NSAIDs.
6. History of asthma, allergic skin disorders, or convulsions.
7. History of chronic systemic diseases (renal/hepatic failure, cardiovascular disorders).
5 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ghada Mohamed Shams
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghada Shams
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Outpatient Clinic of Dermatology, Venereology and Andrology Department at Benha University Hospitals
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Combination therapy for warts
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.